Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wiednig, M.
Successful treatment of acute hereditary angioedema attacks with self-administered icatibant in patients with venous access problems.
BMJ Case Rep. 2013; 2013(5):
Doi: 10.1136/bcr-2013-009320
(- Case Report)
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Wiednig Michaela
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Hereditary angioedema is a rare and potentially fatal autosomal dominant disorder characterised by unpredictable skin, gastrointestinal tract or respiratory tract oedema. Plasma-derived C1-esterase inhibitors are effective in the prophylaxis or treatment of hereditary angioedema type I and II attacks, but must be administered intravenously. This may be problematic in patients with venous access difficulties. Icatibant, a bradykinin B2-receptor antagonist, is administered subcutaneously. In July 2008 icatibant received approval for healthcare professional-administered treatment of hereditary angioedema attacks in adults. In 2011 it received European Medicines Agency and US Food and Drug Administration licences for patient-administered treatment of hereditary angioedema attacks. Given these approvals, and with the appropriate training, icatibant could provide the opportunity for patients to self-administer treatment. This is one of the first long-term follow-up reports of patients with hereditary angioedema using self-administered icatibant. During follow-up, icatibant remained effective and patient satisfaction was high.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Angioedemas, Hereditary - drug therapy
- Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
- Bradykinin - administration & dosage
- Female -
- Humans -
- Middle Aged -
- Patient Satisfaction -
- Self Administration -